AlloVir, Inc. (NASDAQ:ALVR – Get Free Report)’s share price rose 1% during trading on Monday . The company traded as high as $0.78 and last traded at $0.76. 42,495 shares changed hands during mid-day trading, a decline of 94% from the average daily volume of 688,295 shares. The stock had previously closed at $0.75.
AlloVir Stock Performance
The firm has a market cap of $87.40 million, a PE ratio of -0.46 and a beta of 0.78. The stock has a 50-day simple moving average of $0.76 and a two-hundred day simple moving average of $0.76.
AlloVir (NASDAQ:ALVR – Get Free Report) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.05. As a group, sell-side analysts anticipate that AlloVir, Inc. will post -0.5 EPS for the current fiscal year.
Institutional Investors Weigh In On AlloVir
About AlloVir
Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.
Recommended Stories
- Five stocks we like better than AlloVir
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- The 3 Best Fintech Stocks to Buy Now
- 5 Oversold Stocks to Buy Right Now
Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.